169 related articles for article (PubMed ID: 16178478)
1. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?
Martikainen TA; Teppo AM; Grönhagen-Riska C; Ekstrand AV
Perit Dial Int; 2005; 25(5):453-60. PubMed ID: 16178478
[TBL] [Abstract][Full Text] [Related]
2. Effects of Icodextrin and Glucose Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids on Effluent Cell Population and Biocompatibility Markers IL-6 and CA125 in Incident Peritoneal Dialysis Patients.
Opatrná S; Pöpperlová A; Lysák D; Fuchsová R; Trefil L; Racek J; Topolčan O
Ther Apher Dial; 2016 Apr; 20(2):149-57. PubMed ID: 26929256
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.
Parikova A; Zweers MM; Struijk DG; Krediet RT
Adv Perit Dial; 2003; 19():186-90. PubMed ID: 14763059
[TBL] [Abstract][Full Text] [Related]
4. Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? A 1-year follow-up study.
Martikainen T; Ekstrand A; Honkanen E; Teppo AM; Grönhagen-Riska C
Scand J Urol Nephrol; 2005; 39(5):410-6. PubMed ID: 16257844
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory factors for hypoalbuminemia in Japanese peritoneal dialysis patients.
Shioya M; Yoshida T; Kasai K; Furuya R; Kato A; Mori N; Matsumoto Y; Kumagai H
Nephrology (Carlton); 2013 Aug; 18(8):539-44. PubMed ID: 23718260
[TBL] [Abstract][Full Text] [Related]
6. Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.
Yung S; Lui SL; Ng CK; Yim A; Ma MK; Lo KY; Chow CC; Chu KH; Chak WL; Lam MF; Yung CY; Yip TP; Wong S; Tang CS; Ng FS; Chan TM
Perit Dial Int; 2015; 35(2):147-58. PubMed ID: 25904773
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group.
Posthuma N; ter Wee PM; Donker AJ; Oe PL; Peers EM; Verbrugh HA
Perit Dial Int; 2000; 20 Suppl 2():S106-13. PubMed ID: 10911654
[TBL] [Abstract][Full Text] [Related]
8. Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane.
Moriishi M; Kawanishi H; Watanabe H; Tsuchiya S
Adv Perit Dial; 2005; 21():21-4. PubMed ID: 16686279
[TBL] [Abstract][Full Text] [Related]
9. Icodextrin and intraperitoneal inflammation.
Moriishi M; Kawanishi H
Perit Dial Int; 2008 Jun; 28 Suppl 3():S96-S100. PubMed ID: 18552274
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.
Opatrna S; Lysak D; Trefil L; Parker C; Topley N
Perit Dial Int; 2012; 32(1):37-44. PubMed ID: 22302924
[TBL] [Abstract][Full Text] [Related]
11. Nutritional effects of increasing dialysis dose by adding an icodextrin daytime dwell to Nocturnal Intermittent Peritoneal Dialysis (NIPD) in children.
van Hoeck KJ; Rusthoven E; Vermeylen L; Vandesompel A; Marescau B; Lilien M; Schroder CH
Nephrol Dial Transplant; 2003 Jul; 18(7):1383-7. PubMed ID: 12808177
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal protein losses and cytokine generation in automated peritoneal dialysis with combined amino acids and glucose solutions.
Tjiong HL; Zijlstra FJ; Rietveld T; Wattimena JL; Huijmans JG; Swart GR; Fieren MW
Mediators Inflamm; 2007; 2007():97272. PubMed ID: 18274646
[TBL] [Abstract][Full Text] [Related]
13. Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients.
Yoon HE; Chang YK; Shin SJ; Choi BS; Kim BS; Park CW; Song HC; Yoon SA; Jin DC; Kim YS
J Korean Med Sci; 2014 Sep; 29(9):1217-25. PubMed ID: 25246739
[TBL] [Abstract][Full Text] [Related]
14. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2006; 22():24-8. PubMed ID: 16983933
[TBL] [Abstract][Full Text] [Related]
15. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
[TBL] [Abstract][Full Text] [Related]
16. Icodextrin metabolism and alpha-amylase activity in nonuremic rats undergoing chronic peritoneal dialysis.
García-López E; Pawlaczyk K; Anderstam B; Qureshi AR; Kuzlan-Pawlaczyk M; Heimbürger O; Werynski A; Lindholm B
Perit Dial Int; 2007; 27(4):415-23. PubMed ID: 17602150
[TBL] [Abstract][Full Text] [Related]
17. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
18. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.
Krediet RT
Perit Dial Int; 2001; 21(6):560-7. PubMed ID: 11783764
[TBL] [Abstract][Full Text] [Related]
19. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions.
Lee JH; Reddy DK; Saran R; Moore HL; Twardowski ZJ; Nolph KD; Khanna R
Perit Dial Int; 2000; 20(6):643-51. PubMed ID: 11216553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]